Patrick Daly

DocwireNews

Recently, the novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, belumosudil, was approved for the treatment of chronic graft-versus-host disease (GVHD) in patients who failed at least 2 prior lines of therapy. However, the effects of belumosudil on the pharmacokinetics of other immunosuppressive therapies (ISTs) are unknown, according to a presentation at the <a href="https://www.hematology.org/Meetings/Annual-Meeting" target="_blank" rel="noopener">64th ASH Annual Meeting and Exposition</a>.
Researchers, led by Eric Gaskill, examined plasma concentrations of tacrolimus or sirolimus in patients with chronic GVHD who received belumosudil and determined it had a clinically significant impact on IST pharmacokinetics, requiring dose adjustments.
<h3>Belumosudil Impacts Tacrolimus or Sirolimus Concentration</h3>
The study retrospectively enrolled 30 patients with chronic GVHD who received belumosudil concurrently with tacrolimus (n=12) or sirolimus (n=26) at the Moffitt Cancer Center between February 2019 and July 2022. Authors noted tacrolimus and sirolimus typically had target concentration ranges of 3-7 ng/mL and 5-10 ng/mL, respectively. Concentration to dose (C-D) ratios were measured at baseline and at 3 points during treatment.
Of note, patients on sirolimus (P&lt;.001) or tacrolimus (P=.014) who initiated belumosudil had significant increases in mean C-D ratio from baseline to all points during concurrent belumosudil treatment. In addition, a higher proportion of patients on concurrent belumosudil had supratherapeutic levels (tacrolimus, 25%; sirolimus, 62%). Researchers found most tacrolimus levels returned to therapeutic ranges after dose adjustments; however, sirolimus levels were more likely to remain at supratherapeutic levels even after dose adjustments.
Due to the different tacrolimus and sirolimus C-D ratios at each point during belumosudil treatment, the authors suggested this combination may require multiple dose adjustments. They also determined a “significant risk” if this drug interaction is left unsupervised, as 12 of the 26 sirolimus patients had sirolimus concentrations &gt;15 ng/mL.
Ultimately, the authors proposed that “empiric dose reductions of at least 25% for [sirolimus] and [tacrolimus] should be considered with co-administration of [belumosudil], with close monitoring of IST levels at baseline and periodically during initial months of concurrent therapy.”
More From SUO: <a href="https://www.docwirenews.com/conference-coverage/itacitinib-potentially-superior-to-corticosteroids-in-gvhd/">Itacitinib Potentially Superior to Corticosteroids in GVHD</a>

Emily Menendez

Non-Invasive NETseq Classifier Determines NET Diagnosis With High Accuracy, Sensitivity

GEP-NETs

High Tumor Mutational Burden Linked to Worse OS, RFS in Patients with HCC

Hepatocellular Carcinoma

Cecilia Brown

IASLC and LCRF Award Team Science Grant for Work on Immune-Based Approaches to Target Drug-Resistant Lung Cancer Cells

Lung Cancer

Latest News

Belumosudil Significantly Affects IST Serum Concentrations

ASH Annual Meeting 2022

Recently, the novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, belumosudil, was approved for the treatment of chronic graft-versus-host disease ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe